CZ287299B6 - Opioidal peptide, pharmaceutical preparation containing thereof and use of this peptide - Google Patents

Opioidal peptide, pharmaceutical preparation containing thereof and use of this peptide Download PDF

Info

Publication number
CZ287299B6
CZ287299B6 CZ1998401A CZ40198A CZ287299B6 CZ 287299 B6 CZ287299 B6 CZ 287299B6 CZ 1998401 A CZ1998401 A CZ 1998401A CZ 40198 A CZ40198 A CZ 40198A CZ 287299 B6 CZ287299 B6 CZ 287299B6
Authority
CZ
Czechia
Prior art keywords
phe
peptide
tyr
ala
opioid peptide
Prior art date
Application number
CZ1998401A
Other languages
Czech (cs)
English (en)
Other versions
CZ40198A3 (cs
Inventor
Wuyi Wang
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of CZ40198A3 publication Critical patent/CZ40198A3/cs
Publication of CZ287299B6 publication Critical patent/CZ287299B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ1998401A 1995-08-18 1996-08-14 Opioidal peptide, pharmaceutical preparation containing thereof and use of this peptide CZ287299B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides

Publications (2)

Publication Number Publication Date
CZ40198A3 CZ40198A3 (cs) 1998-08-12
CZ287299B6 true CZ287299B6 (en) 2000-10-11

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ1998401A CZ287299B6 (en) 1995-08-18 1996-08-14 Opioidal peptide, pharmaceutical preparation containing thereof and use of this peptide

Country Status (27)

Country Link
US (1) US6337319B1 (ru)
EP (1) EP0845003B1 (ru)
JP (1) JPH11512086A (ru)
KR (1) KR19990037677A (ru)
CN (1) CN1200127A (ru)
AR (1) AR003475A1 (ru)
AT (1) ATE210148T1 (ru)
AU (1) AU711862B2 (ru)
BR (1) BR9610248A (ru)
CA (1) CA2229797A1 (ru)
CZ (1) CZ287299B6 (ru)
DE (1) DE69617699T2 (ru)
DK (1) DK0845003T3 (ru)
EE (1) EE9800048A (ru)
ES (1) ES2171224T3 (ru)
HU (1) HUP9901209A3 (ru)
IL (1) IL123258A (ru)
IS (1) IS4664A (ru)
NO (1) NO980592D0 (ru)
NZ (1) NZ315809A (ru)
PL (1) PL325113A1 (ru)
RU (1) RU2165432C2 (ru)
SE (1) SE9503924D0 (ru)
SK (1) SK282469B6 (ru)
TR (1) TR199800258T1 (ru)
TW (1) TW424095B (ru)
WO (1) WO1997007130A1 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7825231B2 (en) 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
AU2007317817B2 (en) 2006-11-10 2012-09-20 Cara Therapeutics, Inc. Synthetic peptide amides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
EP2273983B1 (en) * 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PL2456427T3 (pl) 2009-07-22 2015-07-31 Gruenenthal Gmbh Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EA201401139A1 (ru) 2012-04-18 2015-03-31 Грюненталь Гмбх Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926269T2 (de) * 1988-06-30 1996-08-14 Astra Ab Dermorphin-Analoge, deren Herstellungsverfahren, pharmazeutische Zusammensetzungen und Methode zur therapeutischen Behandlung unter Verwendung der Analoge
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
NZ315809A (en) 1999-05-28
DK0845003T3 (da) 2002-07-15
CZ40198A3 (cs) 1998-08-12
DE69617699D1 (de) 2002-01-17
IS4664A (is) 1998-02-04
CN1200127A (zh) 1998-11-25
IL123258A (en) 2003-03-12
TR199800258T1 (xx) 1998-05-21
AU711862B2 (en) 1999-10-21
AR003475A1 (es) 1998-08-05
NO980592L (no) 1998-02-11
ES2171224T3 (es) 2002-09-01
SK282469B6 (sk) 2002-02-05
NO980592D0 (no) 1998-02-11
WO1997007130A1 (en) 1997-02-27
DE69617699T2 (de) 2003-08-07
AU6760096A (en) 1997-03-12
PL325113A1 (en) 1998-07-06
US6337319B1 (en) 2002-01-08
TW424095B (en) 2001-03-01
SE9503924D0 (sv) 1995-11-07
EP0845003B1 (en) 2001-12-05
EE9800048A (et) 1998-08-17
RU2165432C2 (ru) 2001-04-20
JPH11512086A (ja) 1999-10-19
HUP9901209A3 (en) 2000-12-28
HUP9901209A2 (hu) 1999-08-30
ATE210148T1 (de) 2001-12-15
SK20398A3 (en) 1998-12-02
IL123258A0 (en) 1998-09-24
CA2229797A1 (en) 1997-02-27
KR19990037677A (ko) 1999-05-25
BR9610248A (pt) 1999-07-06
EP0845003A1 (en) 1998-06-03

Similar Documents

Publication Publication Date Title
CZ287299B6 (en) Opioidal peptide, pharmaceutical preparation containing thereof and use of this peptide
EP0746567B1 (en) Novel opioid peptides for the treatment of pain and use thereof
US5312899A (en) Dermorphin analogs
JP4081501B2 (ja) 新規カッパレセプター選択的オピオイドペプチド
US4518711A (en) Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
WO2000055189A1 (en) Dalda analogs and their use
US5602100A (en) Dermorphin analogs having pharmacological activity
US20030032774A1 (en) Novel opioid peptides for the treatment of pain
US5326751A (en) Enkephalin analogs
AU690648C (en) Novel opioid peptides for the treatment of pain and use thereof
MXPA98001192A (en) New opioid peptides
CA2405724C (en) Substance p analogs for the treatment of cancer
EP1164141A2 (en) Opioid peptides and their use for treatment of pain
RU2146681C1 (ru) Опиоидные пептиды и фармацевтическая композиция
Zadina et al. Mu-Opiate receptor peptides
UA55369C2 (ru) Пептид и фармацевтическая композиция, которые способны ингибировать секрецию пепсина
JPH07116234B2 (ja) 新規ペプチド
JPH10330399A (ja) 神経伝達ポリペプチド
JP2007261958A (ja) ペプチド誘導体

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20020814